Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Stanford and Cellares plan automated stem-cell therapy testing

Cellares will support automated manufacturing and release assays for gene-edited haematopoietic stem-cell therapies under development at Stanford Medicine. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.

Published by
GEN — Genetic Engineering & Biotechnology News
Evidence type
Industry

GEN reports: Cellares will support automated manufacturing and release assays for gene-edited haematopoietic stem-cell therapies under development at Stanford Medicine.

The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance. Consult the linked GEN report for the source organisation’s full announcement.

Biosensors & Diagnostics

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.

Prefer to talk it through? Book a 30-minute discovery call

Stanford and Cellares plan automated stem-cell therapy testing | Brilliant Blue Biosciences